Cardioxyl Raises Series B Led By OrbiMed

Cardioxyl Pharmaceuticals has secured $28 million in a Series B financing led by OrbiMed Advisors. New investor Osage University Partners joined OrbiMed and returning investors New Enterprise Associates and The Aurora Funds in the financing.

PE HUB Community

Join the 12523 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget